AML Characterization Panel
- Sample Type
- Bone Marrow
- Fasting
- No
- Unit
- Percentage/Qualitative
Function
The Acute Myeloid Leukemia (AML) Characterization Panel is a comprehensive set of diagnostic tests used to define the specific subtype and molecular profile of AML. This is not a single test but a combination of morphology (looking at cells), Flow Cytometry (identifying surface markers), Cytogenetics (looking at chromosomes like t(8;21)), and Molecular Testing (checking for mutations like FLT3, NPM1, or IDH1/2). This characterization is the cornerstone of 'Precision Medicine' in leukemia.
Why it is Ordered
Once a preliminary diagnosis of leukemia is made, this panel is essential for:
- Risk Stratification: Determining if the leukemia is 'favorable', 'intermediate', or 'adverse' risk.
- Targeted Therapy: Identifying if specific drugs (like FLT3 inhibitors) will be effective.
- Prognostic Mapping: Predicting the likelihood of remission and the necessity of a stem cell transplant.
- Baseline for MRD: Establishing the unique markers used to track 'Minimal Residual Disease' after treatment.
Associated Conditions
- Acute Myeloid Leukemia (AML): The primary condition, characterized by the rapid growth of abnormal myeloblasts.
- Myelodysplastic Syndrome (MDS): Often a precursor to AML; the panel helps determine if transformation has occurred.
- Leukemoid Reaction: A severe but non-cancerous increase in white blood cells that this panel can rule out.
Why Context Matters
The interpretation of an AML panel is highly complex and depends on the quality of the bone marrow aspirate. If the sample is 'hemodiluted' (mixed with too much peripheral blood), the blast percentage may be falsely low, leading to a misdiagnosis. Additionally, molecular mutations can be missed if the laboratory's sensitivity (depth of sequencing) is low. Given that treatment involves intensive chemotherapy or transplant, a second opinion from a specialized hematopathologist at a major cancer center is standard practice to confirm the mutation profile.
Lab ranges are statistical averages, not biological laws. "Normal" for a 20-year-old male isn't normal for a 60-year-old female.
Clinical References
Source-of-truth databases and clinical guidelines for AML Characterization Panel:
Official Sources
Research & Guidelines
Related Indicators
Medically Reviewed by Dr. Binoy Babu, MBBS
Board Certified Doctor • 10+ Years Clinical Experience
Dr. Babu is a practicing physician dedicated to empowering patients with clear, actionable medical information. He founded 2opi to bridge the gap between complex lab reports and patient understanding, ensuring everyone has access to a reliable second opinion.
Get Notified When Dr. Babu Is Available